News

Servier, which took the responsibility of the CALM Phase 1 study, purchased exclusive rights of UCART19 from Cellectis in 2015.  Last August, the CALM study was started in

Key highlights include: Pelican was the recipient of a highly competitive $15.2m New Company Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT), which

BerGenBio’s lead candidate BGB324 is a first in class, highly selective, potent and orally available small molecule Axl kinase inhibitor in clinical development in a variety of cancer

Plans include the development of a new R&D center and advanced manufacturing and packaging facility that will serve as the US headquarters for Apotex and the US offices for Apobiologix, the company’s biosimilar

The JV, BeiGene Biologics, will build the facility in Guangzhou, Guangdong Province. The project is expected to break ground this year. BeiGene Biologics will use some of the funding to

The Company remains completely blinded to the data from this analysis. BGS-649 is a novel once weekly oral aromatase inhibitor in development as a first-line therapy for the

Aptuit and BioVersys hope that innovative approaches can address antibiotic resistance in the treatment of serious infections. BioVersys is focused on the development of small molecules interfering with

Ledaga is formulated as a topical, once-daily and colorless gel. MF-CTCL is a rare and potentially life-threatening immune system cancer that forms on the skin. It is the common

Waking up at least two times per night to urinate is known as nocturnal polyuria, overproduction of urine during the night. Noctiva, which is a vasopressin analog, is